Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17190669 | 0.85 | PIK3CD (0.37) | PIK3CDALDH1A1TRPM8 | |
| SCHEMBL7980290 | 0.82 | PIK3CD (0.46) | PIK3CD | |
| SCHEMBL9462834 | 0.81 | ADH1B (0.42) | PIK3CDALDH1A1TRPM8 | |
| SCHEMBL5987490 | 0.79 | PIK3CD (0.47) | PIK3CDALDH1A1 | |
| SCHEMBL11532323 | 0.79 | ADH1C (0.45) | ALDH1A1TRPM8 | |
| SCHEMBL15342467 | 0.78 | L3MBTL3 (0.34) | PIK3CDALDH1A1 | |
| SCHEMBL14276844 | 0.78 | PIK3CD (0.33) | PIK3CDALDH1A1 | |
| SCHEMBL13744730 | 0.78 | ALDH1A1 (0.33) | PIK3CDALDH1A1 | |
| SCHEMBL616629 | 0.76 | SLC6A2 (0.40) | PIK3CD | |
| Hydrochloric Acid SCHEMBL618335 | 0.74 | SLC6A2 (0.40) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | OLIPASS CORPORATION (KR) | 2019-11-07 | — | — | US | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | PIK3CD 3491/4885ALDH1A1 2699/4885TRPM8 625/4885 |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | PTBP1, RBM17, UPF1 | PIK3CD 3828/4885ALDH1A1 4196/4885TRPM8 2144/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | PIK3CD 2715/4885ALDH1A1 3390/4885TRPM8 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.